AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.75 |
Market Cap | 103.48M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.24 |
PE Ratio (ttm) | -1.23 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.81 |
Volume | 479,835 |
Avg. Volume (20D) | 1,935,972 |
Open | 2.97 |
Previous Close | 2.91 |
Day's Range | 2.67 - 2.97 |
52-Week Range | 1.61 - 12.74 |
Beta | undefined |
About MGX
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and lice...
Analyst Forecast
According to 7 analyst ratings, the average rating for MGX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 478.66% from the latest price.